尿路上皮癌的免疫治疗研究新进展  

Research advances in immunotherapy for urothelial carcinoma

作　　者：韩馥馨 李晓燕[1] 张素洁[1] 胡毅[1] HAN Fuxin;LI Xiaoyan;ZHANG Sujie;HU Yi(Department of Medical Oncology,the First Medical Center,Chinese PLA General Hospital,Beijing 100853,China)

机构地区：[1]解放军总医院第一医学中心肿瘤内科,北京100853

出　　处：《解放军医学院学报》2020年第12期1247-1251,共5页Academic Journal of Chinese PLA Medical School

基　　金：军队保健专项科研课题(19BJZ15)。

摘　　要：近几年,免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)在治疗多种恶性肿瘤时显示出良好的疗效和安全性。Atezolizumab、Pembrolizumab等5种ICIs已被美国FDA批准用于尿路上皮癌的治疗。NCCN指南更新的内容也包括将新批准的ICIs纳入局部晚期或转移性尿路上皮癌患者的治疗方案。免疫治疗的安全性及生存获益情况令人鼓舞,但获益人群的筛选是目前免疫治疗的主要挑战。本文将对免疫抑制剂应用于尿路上皮癌治疗的研究进展作一综述。In recent years,immune checkpoint inhibitors(ICIs)have shown good efficacy and safety in the treatment of several malignant tumors.Five ICIs have been approved by the U.S.FDA for the treatment of urothelial carcinoma.The NCCN guidelines have also incorporated these five ICIs into treatment regimens for patients with locally advanced or metastatic urothelial carcinoma(UC).Although the safety and survival benefits of immunotherapy are encouraging,screening of patients who can benefit is a major challenge.This article reviews the research progress in ICIs for the treatment of UC.

关 键 词：尿路上皮癌 免疫检查点抑制剂 程序性死亡受体-1/程序性死亡配体-1 免疫治疗 生物标志物 

分 类 号：R737.1[医药卫生—肿瘤]